Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

25.55 USD -1.20 (-4.49%)
Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open. 
From GlobeNewswire News Releases
Esperion and Oberland Capital Announce $200 Million Funding Agreement
Esperion (Nasdaq: ESPR) and an investor group led by Oberland Capital Management LLC (Oberland Capital) today announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of... 
From GlobeNewswire News Releases
Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. 
From GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: 
From GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019. 
From GlobeNewswire News Releases
Biotech Stocks: Why Expensive U.S. Drug Trials are Pushing Pharma Research Overseas
Financialnewsmedia.com News Commentary 
From PR Newswire
Biotech Stocks: Why Expensive U.S. Drug Trials Are Pushing Pharma Research Overseas
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Esperion to Host Analyst and Investor Day Event on May 30
Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time. The event will feature presentations from... 
From GlobeNewswire News Releases
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
Esperion (Nasdaq: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has accepted both New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet... 
From GlobeNewswire News Releases
Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors
Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached... 
From PR Newswire
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
Esperion (NASDAQ:ESPR) announced today that results from the 345 patient, 24-week, Phase 3, double-blind, placebo-controlled study of bempedoic acid (CLEAR Serenity, also known as Study 3) were... 
From GlobeNewswire News Releases
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
Esperion (NASDAQ:ESPR) today announced the Phase 3 results from Study 2 (1002-047, also known as CLEAR Wisdom) of bempedoic acid were presented at the American College of Cardiology Scientific Sessions... 
From GlobeNewswire News Releases
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Esperion (NASDAQ:ESPR) announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today... 
From GlobeNewswire News Releases
New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Advance Auto Parts, Inc.... 
From GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical... 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for... 
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR). Investors in shares of Esperion Therapeutics, Inc.... 
From GlobeNewswire News Releases
Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
Esperion Therapeutics (NASDAQ: ESPR) today announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic... 
From GlobeNewswire News Releases
Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
Esperion (NASDAQ:ESPR), today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions... 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind American Vanguard, Pioneer Natural Resources, American States Water, Groupon, Esperion Therapeutics, and Paylocity Holding — New Horizons, Emerging Trends,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Vanguard... 
From GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
Esperion (NASDAQ: ESPR) today announced completion of the Phase 3 LDL-C Lowering Development Program of bempedoic acid and positive cumulative results. The program consisted of four, pivotal, Phase 3,... 
From GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
Esperion (NASDAQ: ESPR) today announced positive top-line results from its global, pivotal Phase 3 clinical study (Study 2 or 1002-047). This trial was a 52-week, randomized, double-blind,... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.